Opko Health Rating Reiterated by Barrington Research (OPK)
Opko Health (NYSE:OPK)‘s stock had its “buy” rating reiterated by equities researchers at Barrington Research in a research report issued on Monday, AnalystRatingsNetwork.com reports. They currently have a $2.89 price objective on the stock. Barrington Research’s price objective points to a potential downside of 65.88% from the stock’s previous close.
Shares of Opko Health (NYSE:OPK) traded down 0.59% on Monday, hitting $8.43. 1,418,408 shares of the company’s stock traded hands. Opko Health has a 1-year low of $4.05 and a 1-year high of $10.00. The stock has a 50-day moving average of $8.09 and a 200-day moving average of $7.35. The company’s market cap is $2.839 billion.
Separately, analysts at Jefferies Group raised their price target on shares of Opko Health (NYSE:OPK) from $9.00 to $10.00 in a research note to investors on Monday. They now have a “buy” rating on the stock.
OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national pharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.